证券代码：002566 证券简称：益盛药业 公告编号：2023-032 吉林省集安益盛药业股份有限公司 关于召开 2023 年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会届次：2023 年第二次临时股东大会。 2、股东大会的召集人：公司董事会。2023年10月26日，公司第八届董事会 第九次会议审议通过了《关于召开2023年第二次临时股东大会的议案》。 3、会议召开的合法、合规性：本次股东大会会议的召开符合有关法律、行 政法规、部门规章、规范性文件和公司章程的有关规定。 4、会议召开的日期、时间： 现场会议召开时间：2023 年 11 月 22 日（星期三）下午 14:30 。 网络投票时间：2023 年 11 月 22 日。 其中：通过深圳证券交易所交易系统进行网络投票的具体时间为 2023 年 11 月 22 日上午 9:15—9:25,9:30-11:30，下午 13:00-15:00；通过深圳证券交易所 互联网投票的具体时间为 2023 年 11 月 22 日 9:15-15:00 期间 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥469,428,507.08, representing a 9.57% increase compared to ¥428,409,146.26 in the same period last year[24]. - The net profit attributable to shareholders of the listed company was ¥47,428,322.86, an increase of 8.25% from ¥43,812,015.69 year-on-year[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥36,945,048.36, up 12.58% from ¥32,817,432.17 in the previous year[24]. - The net cash flow from operating activities increased by 60.55% to ¥116,279,461.95, compared to ¥72,426,598.89 in the same period last year[24]. - The total assets at the end of the reporting period were ¥3,012,806,349.84, a 1.56% increase from ¥2,966,606,675.95 at the end of the previous year[24]. - The net assets attributable to shareholders of the listed company were ¥2,185,858,928.66, reflecting a 1.43% increase from ¥2,154,978,185.80 at the end of the previous year[24]. - The basic earnings per share for the reporting period was ¥0.1433, an increase of 8.23% from ¥0.1324 in the same period last year[24]. - The company's cash flow from operating activities increased significantly by 60.55%, amounting to ¥116,279,461.95, compared to ¥72,426,598.89 in the previous year[47]. - The company reported a net increase in cash and cash equivalents of 57.99%, totaling ¥83,657,004.16, compared to ¥52,950,604.57 in the previous year[47]. - The total comprehensive income for the first half of 2023 was CNY 45,953,590.56, down from CNY 81,907,555.86 in the first half of 2022, indicating a decline of 43.8%[138]. Market and Product Development - The company has developed 11 dosage forms and 117 varieties, with 49 products included in the National Basic Medical Insurance Drug List[36]. - The company has established a complete ginseng industry chain, expanding from pharmaceuticals to cosmetics and health foods[36]. - Yisheng Ginseng Cosmetics has developed over 500 products, including facial cleansers, whitening, anti-wrinkle, acne treatment, and body care products, expanding its ginseng industry chain[38]. - The company has obtained 8 invention patents for ginseng-based cosmetics, filling a market gap in China[38]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[134]. - The company aims to leverage technological innovation and market expansion to ensure sustainable development amid a challenging economic environment[32]. Research and Development - The company has received 14 patents and 2 scientific achievements related to ginseng cultivation technology[37]. - The Zhenyuan Capsule, a national medical insurance category B product, has been involved in 147 published papers, with 11 indexed by SCI, demonstrating its efficacy in treating coronary heart disease and related conditions[38]. - The Xinyue Capsule has published 238 academic papers, with 23 indexed by SCI, focusing on coronary heart disease and angina treatment[39]. - The Shengmai Injection, a national medical insurance category A product, is recommended for severe cases of COVID-19 in clinical treatment guidelines[40]. - The company has established long-term partnerships with numerous top-tier hospitals and universities, enhancing its R&D capabilities[47]. Financial Management and Strategy - The company plans not to distribute cash dividends or issue bonus shares[7]. - The company emphasizes brand building as a systematic project, continuously investing to enhance brand market awareness and influence[43]. - The company has established a diverse sales channel strategy, including academic promotion and OTC market expansion, to enhance sales performance[42]. - The company has implemented strict internal control systems to protect the rights of shareholders and creditors, ensuring timely disclosure of major information[77]. - The company aims to enhance shareholder value through strategic investments and operational improvements[149]. Risks and Compliance - The company faces risks related to industry policy adjustments, rising production costs, R&D challenges, inventory price declines, talent shortages, and environmental regulations[65][66]. - The company plans to actively monitor and respond to potential risks to achieve its operational goals for 2023[66]. - The company has not received any administrative penalties for environmental issues during the reporting period[74]. - The company has established a comprehensive emergency response mechanism for environmental pollution incidents, including a specific emergency plan and regular employee training[75]. Shareholder Information - The total number of shares remained unchanged at 330,951,600 during the reporting period[106]. - The major shareholder Zhang Yisheng holds 39.08% of the shares, totaling 129,348,530 shares[111]. - The total number of ordinary shareholders at the end of the reporting period was 26,051[110]. - The company aims to protect the interests of minority investors while resolving the shareholding representation issue[114]. Accounting and Financial Reporting - The financial report for the first half of 2023 has not been audited[123]. - The financial statements are prepared in RMB, with the balance sheet dated June 30, 2023[124]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring the financial statements are true and complete[162]. - The company recognizes deferred tax assets related to deductible temporary differences if new information indicates that the economic benefits can be realized within 12 months post-acquisition, reducing goodwill accordingly[168]. Inventory and Assets - The company recognizes inventory when it is likely that economic benefits will flow to the enterprise and the cost can be reliably measured[195]. - Inventory is measured at the lower of cost and net realizable value, with provisions for inventory write-downs recorded when costs exceed net realizable value[196]. - The company uses a perpetual inventory system for tracking inventory[197]. - The company conducts physical inventory counts of consumable biological assets between July and October each year[199].

吉林省集安益盛药业股份有限公司 （以下无正文） （本页无正文，为《独立董事关于控股股东及其他关联方占用公司资金和公司对 外担保情况的专项说明和独立意见》之签署页） 独立董事： 独立董事关于控股股东及其他关联方占用公司资金 和公司对外担保情况的专项说明和独立意见 根据中国证券监督管理委员会《上市公司独立董事规则》、《上市公司自律 监管指引第1号—主板上市公司规范运作》、《深圳证券交易所股票上市规则》 和《吉林省集安益盛药业股份有限公司章程》等有关规定，作为吉林省集安益盛 药业股份有限公司（以下简称"公司"）的独立董事，我们本着对公司、全体股 东及投资者负责的态度，按照实事求是的原则，对公司2023年半年度控股股东及 其他关联方占用公司资金及公司对外担保情况进行了认真的检查和落实，并作如 下专项说明及独立意见： 1、报告期内公司不存在控股股东及其他关联方占用公司资金情况，也不存 在以前期间发生并延续到报告期的控股股东及其他关联方占用公司资金的情况。 2、报告期内公司不存在为股东、实际控制人及其关联方、任何非法人单位 或个人提供担保的情况，也不存在以前期间发生并延续到报告期的对外担保事项。 公司当期和累计对外担保金 ...

吉林省集安益盛药业股份有限公司（以下称"公司"）第八届董事会第八次 会议通知以当面送达、电话、邮件的方式于2023年8月17日向各董事发出，会议 于2023年8月24日以现场会议的方式在公司四楼会议室召开。会议应参加审议董 事9人，实际参加审议董事9人。本次会议的召开符合《公司法》及《公司章程》 的规定，合法有效。会议由董事长张益胜先生主持，审议并通过了如下议案： 会议以9票同意、0票反对、0票弃权的表决结果，审议通过了《2023年半年 度报告及其摘要》。 《2023年半年度报告全文》详见公司指定信息披露网站巨潮资讯网 (www.cninfo.com.cn)。 《2023年半年度报告摘要》详见公司指定的信息披露媒体巨潮资讯网 （www.cninfo.com.cn）及《中国证券报》、《上海证券报》、《证券时报》。 特此公告。 吉林省集安益盛药业股份有限公司董事会 证券代码：002566 证券简称：益盛药业 公告编号：2023-026 吉林省集安益盛药业股份有限公司 第八届董事会第八次会议决议公告 二〇二三年八月二十四日 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大 ...

上市公司2023年6月非经营性资金占用及其他关联资金往来情况汇总表 编制单位：吉林省集安益盛药业股份有限公司 金额单位：人民币元 | 非经营性资金占 用 | 资金占用方名称 | 占用方与上市公 司的关联关系 | 上市公司核算的 会计科目 | 2023年初占用 资金余额 | 2023年1-6月往来累计发 生金额（不含利息） | 2023年1-6月往来 资金的利息（如有 | 2023年度偿还 累计发生额 | 2023年6月末占 用资金余额 | 占用形成原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | ） | | | | | | 现大股东及其附 | | | | | | | | | | 非经营性占用 | | 属企业 | | | | | | | | | | | | | | | | | | | | | | 非经营性占用 | | 小 计 | —— | —— | —— | | | | | | —— | —— | | 前大股东及其附 | | | | | | | | | | 非经营性占用 | ...

特此公告。 吉林省集安益盛药业股份有限公司监事会 二〇二三年八月二十四日 吉林省集安益盛药业股份有限公司（以下称"公司"）第八届监事会第八次 会议通知以当面送达、电话的方式于2023年8月17日向各监事发出，会议于2023 年8月24日以现场会议方式在公司四楼会议室召开。会议应当出席的监事3人，实 际出席的监事3人。本次会议的召集、召开程序符合《公司法》等有关法律、法 规及《公司章程》的规定。会议由监事会主席于晓静女士主持，审议并通过了如 下议案： 会议以3票同意、0票反对、0票弃权的表决结果，审议通过了《2023年半年 度报告及其摘要》。 经审核，监事会认为董事会编制和审核公司2023年半年度报告的程序符合法 律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了上市公 司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 证券代码：002566 证券简称：益盛药业 公告编号：2023-027 吉林省集安益盛药业股份有限公司 第八届监事会第八次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 ...

证券代码：002566 证券简称：益盛药业 公告编号：2023-025 吉林省集安益盛药业股份有限公司 关于控股子公司完成工商变更登记的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 吉林省集安益盛药业股份有限公司（以下称"公司"）控股子公司益盛汉参化 妆品有限公司因自身业务需要，对经营范围进行了变更，并于近日完成了工商变更 登记手续，取得了由集安市市场监督管理局换发的营业执照。具体变更事项如下： | 变更事项 | 变更前 | 变更后 | | --- | --- | --- | | 经营范围 | 许可项目：化妆品生产；食品销 | 许可项目：化妆品生产；食品销 | | | 售；保健用品（非食品）销售； | 售；保健用品（非食品）销售； | | | 酒类经营；生活美容服务；互联 | 酒类经营；生活美容服务；互联 | | | 网信息服务；道路货物运输（不 | 网信息服务；道路货物运输（不 | | | 含危险货物）。（依法须经批准 | 含危险货物）；第三类医疗器械 | | | 的项目，经相关部门批准后方可 | 经营；用于传染病防治的消毒产 | | | 开展经营 ...

证券代码： 002566 证券简称：益盛药业 吉林省集安益盛药业股份有限公司投资者关系活动记录表 编号：2023-002 | 投资者关系活动 | □特定对象调研 □ 分析师会议 | | --- | --- | | 类别 | □ 媒体采访 √ 业绩说明会 | | | 路演活动 □ 新闻发布会 □ | | | □ 现场参观 | | | □ 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 2023 年 5 月 22 日 (周一) 下午 14:00~16:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 1、总经理薛晓民 | | 员姓名 | 2、董事会秘书李铁军 | | | 3、财务总监毕建涛 | | | 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | 1、近几年公司营收变化总是不大，利润也不高，是什么原 | | | 因？公司业务无法推进吗？ | | | 近三年由于疫 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 证券代码：002566 证券简称：益盛药业 公告编号：2023-013 吉林省集安益盛药业股份有限公司 关于参加网上集体业绩说明会的公告 （问题征集专题页面二维码，扫码自动匹配移动端） 特此公告。 吉林省集安益盛药业股份有限公司董事会 二〇二三年五月十二日 为进一步加强与投资者的互动交流，吉林省集安益盛药业股份有限公司（以 下简称"公司"）将参加由吉林证监局、吉林省证券业协会、深圳市全景网络有 限公司共同举办的"2023年吉林辖区上市公司网上集体业绩说明会"，现将有关 事项公告如下： 本次集体业绩说明会将通过深圳市全景网络有限公司提供的互联网平台举 行，投资者可以登陆全景网"投资者关系互动平台"（http://ir.p5w.net）参与 公司业绩说明会,时间为2023年5月22日（星期一）14:00至16:00。 届时公司总经理薛晓民先生、董事会秘书李铁军先生、财务总监毕建涛先生 将通过网络在线问答互动的形式，与投资者就2022年经营业绩等投资者关注的问 题进行交流。期间，公司高管将全程在线，实时回答投资者的提 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 250,973,766.69, representing an increase of 11.28% compared to CNY 225,540,617.25 in the same period last year[4] - Net profit attributable to shareholders was CNY 28,702,562.15, up by 5.41% from CNY 27,229,639.30 year-on-year[4] - Basic and diluted earnings per share were both CNY 0.0867, reflecting a growth of 5.35% from CNY 0.0823[4] - Operating profit increased to ¥39,719,516.33, reflecting a growth of 18.3% from ¥33,666,091.21 in the last period[16] - Net profit for the current period was ¥31,391,147.16, a rise of 7.4% compared to ¥29,228,860.26 in the previous period[17] Cash Flow and Liquidity - The net cash flow from operating activities increased significantly by 106.11%, reaching CNY 80,326,480.85 compared to CNY 38,973,399.49 in the previous year[4] - Cash flow from operating activities generated a net amount of ¥80,326,480.85, significantly higher than ¥38,973,399.49 in the previous period[20] - Cash and cash equivalents at the end of the period totaled ¥435,152,569.03, compared to ¥200,989,827.14 at the end of the previous period[21] - The company's cash and cash equivalents increased to RMB 435,152,569.03 from RMB 343,263,877.76, representing a growth of approximately 27%[13] - The company reported a net increase in cash and cash equivalents of ¥91,888,691.27, contrasting with a decrease of ¥18,705,189.26 in the prior period[21] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,012,881,593.88, a 1.56% increase from CNY 2,966,606,675.95 at the end of the previous year[4] - Current assets reached RMB 2,359,212,920.22, up from RMB 2,302,612,638.12, indicating an increase of about 2.5%[13] - Total liabilities stood at RMB 732,062,391.35, compared to RMB 717,178,620.58 at the beginning of the year, showing a slight increase of about 2.1%[14] - The company's total equity rose to RMB 2,280,819,202.53 from RMB 2,249,428,055.37, reflecting an increase of approximately 1.4%[14] - Short-term borrowings increased to RMB 470,447,708.34 from RMB 430,427,013.89, marking an increase of about 9.3%[14] Operating Costs and Expenses - Operating costs rose by 31.77% to CNY 70,618,510.44, primarily due to increased revenue[5] - Total operating costs amounted to ¥221,979,729.88, up 11.1% from ¥199,827,029.66 in the prior period[16] - Financial expenses decreased significantly by 71.27%, totaling CNY 749,875.57, attributed to increased interest income from agreement deposits[5] - Research and development expenses rose to ¥5,323,126.61, compared to ¥4,342,941.68 in the previous period, indicating a focus on innovation[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 28,625, with the largest shareholder holding 39.08% of the shares[8] - The company is implementing a rectification plan to address issues related to shareholding disclosure, with certain shareholders no longer having shareholding proxies[10] - The company aims to resolve the shareholding proxy issue in the shortest time possible while considering the impact on the secondary market[10] Regulatory Compliance - The company is focused on ensuring the accuracy and completeness of its financial disclosures following regulatory requirements[10] - The company has not undergone an audit for the first quarter report[22] Government Subsidies and Fair Value Gains - The company received government subsidies amounting to CNY 11,018,215.10, which are closely related to its normal business operations[5] - The company reported a 49.42% increase in fair value gains, amounting to CNY 1,160,582.03, influenced by changes in the value of financial products[5] - The company reported a decrease in inventory from RMB 1,603,100,929.50 to RMB 1,592,167,434.20, a reduction of approximately 0.7%[13]